About Mesa Laboratories, Inc
Mesa Laboratories, Inc. designs, manufactures, and markets quality control instruments and disposable products in the United States, Canada, Europe, and Japan. The company’s Sterilization and Disinfection Control segment manufactures and markets biological indicators comprising spore strips, self-contained products, and culture media, as well as process challenge devices; and offers testing services. This segment also provides chemical and cleaning indicators that are used to assess the effectiveness of sterilization and cleaning processes. Its Instruments segment offers data loggers used in critical manufacturing, quality control, and validation applications; medical meters and calibration solutions used to test various parameters of the dialysis fluid, and the calibration and operation of the dialysis machine; gas flow calibration and air sampling equipment that are used for industrial hygiene assessments, calibration of gas metering equipment, and environmental air sampling; and torque testing systems used for measure bottle cap tightness. This segment’s products are used in healthcare, pharmaceutical, medical device, food and beverage, industrial hygiene, and environmental air sampling industries. The company’s Biopharmaceutical Development segment develops, manufactures, and commercializes automated solutions for protein analysis, which include analysis equipment, CDs, kits, and buffers; and peptide synthesizers to automate chemically synthesized peptides that are used in the creation of peptide therapies, biomaterials, cosmetics, and general research. Its Continuous Monitoring segment offers systems, which are used to monitor temperature, humidity, and differential pressure for use in hospitals, pharmaceutical and medical device manufacturers, blood banks, pharmacies, and laboratory environments. The company was founded in 1982 and is headquartered in Lakewood, Colorado. Address: 12100 West Sixth Avenue, Lakewood, CO, United States, 80228
Mesa Laboratories, Inc News and around…
Latest news about Mesa Laboratories, Inc (MLAB) common stock and company :
Zacks Investment Ideas feature highlights: Edwards Lifesciences, Mesa Laboratories and Sensus Healthcare
These smaller healthcare companies all have 10x potential for investors.
What to Expect From the Markets In 2022
Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...
Mesa Laboratories and Disney have been highlighted as Zacks Bull and Bear of the Day
Another solid quarter and growth ahead in genetic diagnostic services makes this small cap a buy
CFO of Mesa Laboratories Inc (30-Year Financial, Insider Trades) John Sakys (insider trades) sold 1,758 shares of MLAB on 12/10/2021 at an average price of $324.74 a share.
According to Benzinga Pro, during Q2, Mesa Laboratories (NASDAQ:MLAB) earned $4.20 million, a 34.52% increase from the preceding ...
In recent trading, shares of Mesa Laboratories, Inc. (MLAB) have crossed above the average analyst 12-month target price of $315.00, changing hands for $322.78/share..
A Relative Strength Rating upgrade for Mesa Laboratories shows improving technical performance. Will it continue?
Mesa Labs (MLAB) delivered earnings and revenue surprises of 44.96% and 2.55%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?
LAKEWOOD, Colo., Nov. 04, 2021 (GLOBE NEWSWIRE) -- Mesa Laboratories, Inc. (NASDAQ:MLAB) today reported results for its second fiscal quarter (“2Q22”) and six months ended September 30, 2021. Financial highlights for the quarter and six months ended September 30, 2021 as compared to last year: Revenues increased 12% and 14%, respectivelyOperating income decreased 6% and 9%, respectively Non-GAAP adjusted operating income1 excluding unusual items increased 1% and 9%, respectively* Financial Resul
LAKEWOOD, Colo., Oct. 29, 2021 (GLOBE NEWSWIRE) -- Mesa Laboratories, Inc. (NASDAQ:MLAB) announced the appointment of Shiraz Ladiwala to its Board of Directors, effective October 28, 2021. Shiraz previously worked in leadership roles at Thermo Fisher Scientific and retired on August 31, 2021. With Mr. Ladiwala’s appointment, the Mesa Laboratories, Inc. Board of Directors will be comprised of eight directors, six of whom are independent. “Shiraz’s extensive experience building a world class life
Mesa Labs (MLAB) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
The worst result, after buying shares in a company (assuming no leverage), would be if you lose all the money you put...
LAKEWOOD, Colo., Oct. 20, 2021 (GLOBE NEWSWIRE) -- Mesa Laboratories, Inc. (NASDAQ:MLAB) today announced that it has completed the previously announced acquisition of Agena Biosciences, Inc. With this highly strategic acquisition, Agena’s innovative approach to molecular diagnostics is now paired with Mesa’s proven approach to continuous improvement and operational and commercial efficiency. Together, Mesa and Agena will join to pursue the common purpose of Protecting the Vulnerable®. Agena is a
Mesa Labs, Equinox Gold, General Motors, Tesla and Ford Motor highlighted as Zacks Bull and Bear of the Day
The IBD SmartSelect Composite Rating for Mesa Laboratories rose from 94 to 97 Monday.
Mesa Laboratories Inc(NASDAQ: MLAB)has agreed to acquireAgena Bioscience Incfor a cash purchase price of $300 ...
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting ...
Mesa Labs (MLAB) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
John Sakys, CFO at Mesa Laboratories (NASDAQ:MLAB), made a large buy and sell of company shares on September 10, according to a new SEC filing. What Happened: A Form 4 filing from the U.S. Securities and Exchange Commission states that John Sakys purchased 1,400 Mesa Laboratories shares at a price of $89.70 per share for a total of $125,580 on September 10. They then sold their shares on the same day in the open market. They sold at a price of $270.21 to raise a total of $378,294 from the stock
In trading on Thursday, shares of Mesa Laboratories, Inc. (MLAB) crossed below their 200 day moving average of $269.47, changing hands as low as $267.46 per share..
Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. For the Invesco S&P SmallCap Low Volatility ETF (XSLV), we found that the implied analyst target price for the ETF based upon its underlying holdings is $53.24 per unit.
According to Benzinga Pro, during Q1, Mesa Laboratories (NASDAQ:MLAB) earned $3.12 million, a 27.3% increase from the preceding quarter. ...
Mesa Laboratories' (NASDAQ:MLAB) stock is up by 9.5% over the past three months. However, the company's financials look...
In trading on Monday, shares of Mesa Laboratories, Inc. (MLAB) crossed below their 200 day moving average of $269.58, changing hands as low as $267.46 per share..